Page 216 - Eceptor News Today

Monocytes promote viral control during SARS-COV-2 infection The most severe symptoms of COVID-19 are associated with the dysregulation of immune functions in the respiratory tract, in particular, leading to excessive inflammation as the result of a cytokine storm. Upon infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) respiratory epithelial cells or alveolar macrophages respond by producing interferon and various pro-inflammatory cytokines, such as interleukin-6 and tu...

T-cell acute lymphoblastic leukemia is an aggressive cancer type that mostly affects children. The standard treatment is chemotherapy, but about one in four patients do not respond or develop resistance to this.

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern Researchers in Canada and the United States have identified a monoclonal antibody that potently neutralizes variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVIdD-19) pandemic. “LY-CoV1404 is a potent SARS-CoV-2-binding antibody that neutralizes all known variants of concern,” says Bryan Barnhar from AbCellera Biologics Inc. in Vanco...

SARS-CoV-2 study in human gut organoids Most of the major life-threatening symptoms of COVID-19 disease are associated with the hosts generation of an exacerbated pro-inflammatory immune response. Many studies have correlated the intensity of the immune response with the severity of disease. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters cells via the angiotensin-converting enzyme 2 (ACE2) receptor, commonly found on the surface of cells in the lungs, though also with a si...

Differential NK cell activity found to contribute to SARS-CoV-2 infection resistance The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected millions of people worldwide and is the leading cause of mortality in Brazil in 2020 as well as early 2021. Clinical manifestations of COVID-19 disease range from no symptoms and mild flu-like symptoms to severe cases leading to hospitalization and death. Nearly 30% of individuals infected with SARS-CoV...

Evidence that elevated blood glucose is a significant risk factor for severe COVID-19 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus responsible for the outbreak of the COVID-19 disease. The virus emerged in China in late 2019, with viral transmission reaching pandemic proportions in early 2020. The average mortality rate of COVID-19 is under 2%, as this virus also causes asymptomatic infections in a large proportion of the population. However, in a small pe...

Can SARS-CoV-2’s impairment of endothelium cause vascular disease? The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen that causes the coronavirus disease (COVID-19), contains the spike protein that binds with the human angiotensin-converting enzyme 2 (ACE2) receptor to enter and infect host cells. Researchers in the U.S. and China have revealed that SARS-CoV-2s spike protein does not only latch and bind to healthy cells for infection, but also plays a key role in t...

Study reveals new broadly neutralizing and protective antibody against coronaviruses In the setting of potentially reduced vaccine efficacy against coronavirus disease (COVID-19) due to emerging viral variants, the deployment of effective treatments based on monoclonal antibodies may be an additional strategy to help control the pandemic. A new study by US researchers, currently available on the bioRxiv* preprint server, describes the action of a specific antibody known as DH1047. The emergenc...

Researchers develop a nanoparticle-based formulation with anti-SARS-CoV-2 activity A study recently published in the journal Matter has demonstrated the development and validation of a nanoparticle-based formulation, capable of completely inhibiting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection blocking the interaction between viral spike protein and host cell angiotensin-converting enzyme 2 (ACE2). A scanning electron microscope image of a nanotrap (orange) bindin...

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies Measuring the presence and performance of neutralizing antibodies is crucial in the fight against the coronavirus disease 2019 (COVID-19) pandemic. This allows us to glimpse how effective vaccines and antibody therapies are in conferring protective immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Researchers in Germany and the U.S. described 11 unique nanobodies (Nbs) ...